These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 6259002)

  • 1. Additive inhibitory effects of treatment with an LHRH agonist and an antiandrogen on androgen-dependent tissues in the rat.
    Séguin C; Cusan L; Bélanger A; Kelly PA; Labrie F; Raynaud JP
    Mol Cell Endocrinol; 1981 Jan; 21(1):37-41. PubMed ID: 6259002
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New hormonal treatment in cancer of the prostate: combined administration of an LHRH agonist and an antiandrogen.
    Labrie F; Dupont A; Belanger A; Lefebvre FA; Cusan L; Monfette G; Laberge JG; Emond JP; Raynaud JP; Husson JM; Fazekas AT
    J Steroid Biochem; 1983 Jul; 19(1C):999-1007. PubMed ID: 6411995
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined long-term treatment with an LHRH agonist and a pure antiandrogen blocks androgenic influence in the rat.
    Lefebvre FA; Séguin C; Bélanger A; Caron S; Sairam MR; Raynaud JP; Labrie F
    Prostate; 1982; 3(6):569-78. PubMed ID: 6296803
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characteristics of flutamide action on prostatic and testicular functions in the rat.
    Marchetti B; Labrie F
    J Steroid Biochem; 1988 Jun; 29(6):691-8. PubMed ID: 2838689
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New hormonal therapy in prostate cancer: combined use of a pure antiandrogen and an LHRH agonist.
    Labrie F; Dupont A; Belanger A; Lefebvre FA; Cusan L; Raynaud JP; Husson JM; Fazekas AT
    Horm Res; 1983; 18(1-3):18-27. PubMed ID: 6411578
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The pure antiandrogen RU 23908 (Anandron), a candidate of choice for the combined antihormonal treatment of prostatic cancer: a review.
    Raynaud JP; Bonne C; Moguilewsky M; Lefebvre FA; Bélanger A; Labrie F
    Prostate; 1984; 5(3):299-311. PubMed ID: 6374639
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of the chronic administration of a potent luteinizing hormone releasing hormone analog on the rat prostate.
    Trachtenberg J
    J Urol; 1982 Nov; 128(5):1097-100. PubMed ID: 6294350
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rat prostatic weight regression in reaction to ketoconazole, cyproterone acetate, and RU 23908 as adjuncts to a depot formulation of gonadotropin-releasing hormone analogue.
    Lamberts SW; Uitterlinden P; de Jong FH
    Cancer Res; 1988 Nov; 48(21):6063-8. PubMed ID: 2844399
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [New approach in the treatment of prostatic cancer: combined use of a LHRH agonist and an androgen antagonist].
    Labrie F; Dupont A; Belanger A; Lefebvre FA; Raynaud JP
    J Pharmacol; 1983; 14 Suppl 3():117-35. PubMed ID: 6423907
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of oestrogen and GnRH agonist analogue-induced inhibition of the pituitary-testicular function in rat.
    Huhtaniemi IT; Warren DD; Catt KJ
    Acta Endocrinol (Copenh); 1983 Jun; 103(2):163-71. PubMed ID: 6305079
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of 2-week combination therapy with the luteinizing hormone-releasing hormone (LHRH) agonist [D-Trp6, des-Gly-NH2(10)]LHRH ethylamide and the antiandrogen flutamide on prostate structure and steroid levels in the dog.
    Lacoste D; Dubé D; Bélanger A; Labrie F
    Mol Cell Endocrinol; 1989 Dec; 67(2-3):131-8. PubMed ID: 2693158
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preliminary results on the clinical efficacy and safety of androgen inhibition by an LHRH agonist alone or combined with an antiandrogen in the treatment of prostatic carcinoma.
    Faure N; Lemay A; Laroche B; Robert G; Plante R; Jean C; Thabet M; Roy R; Fazekas AT
    Prostate; 1983; 4(6):601-24. PubMed ID: 6415632
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recovery of gonadal functions in the adult male rat following cessation of five-month daily treatment with an LHRH agonist.
    Lefebvre FA; Bélanger A; Pelletier G; Labrie F
    J Androl; 1984; 5(3):181-92. PubMed ID: 6086556
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of chronic D-Leu6, des-Gly10-gonadotropin releasing hormone ethylamide on male sex tissues.
    Rajfer J; Heber D; Peng S; Swerdloff RS
    Biol Reprod; 1984 Apr; 30(3):646-51. PubMed ID: 6426536
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacology of an antiandrogen, anandron, used as an adjuvant therapy in the treatment of prostate cancer.
    Moguilewsky M; Fiet J; Tournemine C; Raynaud JP
    J Steroid Biochem; 1986 Jan; 24(1):139-46. PubMed ID: 3009970
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Down-regulation of testicular androgen biosynthesis and LH receptor levels by an LHRH agonist: role of prolactin.
    Belanger A; Auclair C; Seguin C; Kelly PA; Labrie F
    Mol Cell Endocrinol; 1979 Jan; 13(1):47-53. PubMed ID: 221286
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Study of the direct action of luteinizing hormone-releasing hormone agonists at the testicular level in intact rats treated with an antiluteinizing hormone serum.
    Séguin C; Bélanger A; Labrie F; Hansel W
    Endocrinology; 1982 Feb; 110(2):524-30. PubMed ID: 6276140
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Inhibitory effects of LHRH on LH receptors in the rat testis].
    Auclair C; Ferland L; Cusan L; Kelly PA; Labrie F; Azadian-Boulanger G; Raynaud JP
    C R Acad Hebd Seances Acad Sci D; 1978 May; 286(18):1305-7. PubMed ID: 208798
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sensitivity of luteinizing hormone and gonadal steroid responses to single intranasal administration of an LHRH agonist (Hoe-766) in young normal adult men.
    Faure N; Labrie F; Belanger A; Lemay A; Raynaud JP; Von der Ohe M; Fazekas AT
    J Endocrinol Invest; 1982; 5(6):355-60. PubMed ID: 6820372
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LHRH and analogues as potential therapy for benign prostatic hyperplasia and hormone-dependent cancers.
    Auclair C; Stern M; Givner ML
    Arch Androl; 1981 Nov; 7(3):237-44. PubMed ID: 6171216
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.